ARCHIVES

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

This article is from The Cancer Letter archive.

Vol. 26 No. 25 | June 23, 2000

Download PDF Visit The Full Archive

Related Articles

House May Add $80 Million To NCI Budget For FY 1984

September 16, 1983

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

Guest Editorial: Gerard Silvestri calls for uniform guideline for CT screening for lung cancer

July 1, 2011

ASCO Updates Guideline On Antiemetics

June 30, 2006

Also: Court Will Reconsider Ruling on Access To Experimental Drugs.

December 1, 2006